ArticleBMJ open2023

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab.

Korinna Karampampa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.